#Canada #Vancouver #financial results #Else Nutrition #plant-based formula

Else Nutrition's Fiscal Year 2025 Financial Overview

Overview
In the recent financial release, Else Nutrition Holdings Inc. (TSX: BABY, OTCQX: BABYF, FSE: 0YL.F) detailed key insights from its fiscal year 2025, which concluded on December 31, 2025. This year has been characterized as a transformative period for the company by its CEO, Hamutal Yitzhak.

Operational Enhancements
Despite facing hurdles like funding shortages and extended product stock-outs, Else Nutrition made significant strides in operational efficiency. The company shifted its strategy in Canada from a distribution model to a more direct retail approach, which allowed it to re-enter major retail markets in early 2026.

Additionally, they revamped their third-party logistics alignments in the U.S., resulting in a streamlined operational process and an impressive 51% cut in total operating expenses year-over-year. Marketing and sales expenditures were reduced by more than 60%, although this intensified cost-cutting did lead to an 18.5% decline in U.S. revenue mainly due to continued stock issues with their cereal and kids' Ready-to-Drink offerings.

Financial Highlights
Despite the revenue drop, positive financial changes emerged. The company's cost of goods sold (COGS) saw a remarkable reduction of 38% compared to the previous year. After adjusting for one-time costs primarily linked to older inventory, the actual fall in COGS was even sharper, nearly twice as high as the revenue decrease. Following these adjustments, Else Nutrition achieved a gross profit of $320 thousand in 2025, a marked improvement from a gross loss of $1.2 million in the previous fiscal year.

Looking forward, managers anticipate a positive trend, estimating that increased sales will drive their Gross Profit Margin (GPM) to 30% or more in 2026.

Future Prospects
The pathway to profitability seems increasingly clear for Else Nutrition as they reported resumed shipments to Canadian retailers at improved margins and noted a rise in online revenue. Plans are in place to reach cash flow breakeven by late 2026 to early 2027.
Importantly, the company is progressing on its plant-based infant formula program, heralding a significant growth opportunity. Recent changes in U.S. regulations are favorable, with the FDA moving toward clearer approval pathways for innovative plant-based formulas, which significantly supports their strategy.

The FDA's recent initiatives signal increasing governmental support for innovation in the sector, opening new doors for plant-based nutritional options. These developments place Else Nutrition in a robust position for future clinical trials and eventual market entry once new guidelines take effect.

Consequently, Else Nutrition remains focused on optimizing costs, enhancing manufacturing processes, and expanding market efforts. The leadership team feels optimistic about sustaining the momentum gained into 2026 and beyond. Their commitment reflects on the long-term value they aim to bring to their shareholders while addressing the growing need for inclusive nutrition strategies.